Seminars in Oncology
Volume 32, Issue 1 , Pages 113-119 , February 2005

Pharmacogenetic influences on treatment response and toxicity in colorectal cancer

  • Benjamin R. Tan

      Affiliations

    • Department of Medicine and The Siteman Cancer Center, Washington University School of Medicine, St Louis, MO
    • ,
  • Howard L. McLeod

      Affiliations

    • Department of Medicine and The Siteman Cancer Center, Washington University School of Medicine, St Louis, MO
    • Corresponding Author InformationAddress reprint requests to Dr Howard L. McLeod, Washington University School of Medicine, 660 S Euclid Ave, Box 8069, St Louis, MO 63110

References 

  1. Vesell ES . Advances in pharmacogenetics and pharmacogenomics . J Clin Pharmacol . 2000;40:930–938
  2. Vesell ES . Genetic and environmental factors causing variation in drug response . Mutat Res . 1991;247:241–257
  3. Vesell ES . Pharmacogenetic perspectives gained from twin and family studies . Pharmacol Ther . 1989;41:535–552
  4. Evans WE , McLeod HL . Pharmacogenomics—Drug disposition, drug targets, and side effects . N Engl J Med . 2003;348:538–549
  5. McLeod HL , Evans WE . Pharmacogenomics (Unlocking the human genome for better drug therapy) . Annu Rev Pharmacol Toxicol . 2001;41:101–121
  6. Sachidanandam R , Weissman D , Schmidt SC , et al.   A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms . Nature . 2001;409:928–933
  7. McLeod HL . Individualized cancer therapy (Molecular approaches to the prediction of tumor response) . Expert Rev Anticancer Ther . 2002;2:113–119
  8. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project . J Clin Oncol . 1992;10:896–903
  9. Meta-analysis Group in Cancer . Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer . J Clin Oncol . 1998;16:301–308
  10. Lenz HJ , Danenberg KD , Leichman CG , et al.   p53 and thymidylate synthase expression in untreated stage II colon cancer (Associations with recurrence, survival, and site) . Clin Cancer Res . 1998;4:1227–1234
  11. Johnston PG , Lenz HJ , Leichman CG , et al.   Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors . Cancer Res . 1995;55:1407–1412
  12. Johnston PG , Fisher ER , Rockette HE , et al.   The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer . J Clin Oncol . 1994;12:2640–2647
  13. Marsh S , McKay JA , Curran S , et al.   Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis . Oncol Rep . 2002;9:231–234
  14. Gorlick R , Metzger R , Danenberg KD , et al.   Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma . J Clin Oncol . 1998;16:1465–1469
  15. Findlay MP , Cunningham D , Morgan G , et al.   Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy . Br J Cancer . 1997;75:903–909
  16. McKay JA , Lloret C , Murray GI , et al.   Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas . Int J Oncol . 2000;17:153–158
  17. Link KH , Kornmann M , Butzer U , et al.   Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy . Cancer . 2000;89:288–296
  18. Kornmann M , Link KH , Lenz HJ , et al.   Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy . Cancer Lett . 1997;118:29–35
  19. Marsh S , Collie-Duguid ES , Li T , et al.   Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations . Genomics . 1999;58:310–312
  20. Pullarkat ST , Stoehlmacher J , Ghaderi V , et al.   Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy . Pharmacogenomics J . 2001;1:65–70
  21. Marsh S , McKay JA , Cassidy J , et al.   Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer . Int J Oncol . 2001;19:383–386
  22. Villafranca E , Okruzhnov Y , Dominguez MA , et al.   Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer . J Clin Oncol . 2001;19:1779–1786
  23. Iacopetta B , Grieu F , Joseph D , et al.   A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil . Br J Cancer . 2001;85:827–830
  24. Heggie GD , Sommadossi JP , Cross DS , et al.   Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile . Cancer Res . 1987;47:2203–2206
  25. Diasio RB , Harris BE . Clinical pharmacology of 5-fluorouracil . Clin Pharmacokinet . 1989;16:215–237
  26. Etienne MC , Lagrange JL , Dassonville O , et al.   Population study of dihydropyrimidine dehydrogenase in cancer patients . J Clin Oncol . 1994;12:2248–2253
  27. Lu Z , Zhang R , Diasio RB . Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver (population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy) . Cancer Res . 1993;53:5433–5438
  28. McLeod HL , Collie-Duguid ES , Vreken P , et al.   Nomenclature for human DPYD alleles . Pharmacogenetics . 1998;8:455–459
  29. Ridge SA , Sludden J , Wei X , et al.   Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer . Br J Cancer . 1998;77:497–500
  30. McLeod HL , Sludden J , Murray GI , et al.   Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours . Br J Cancer . 1998;77:461–465
  31. Johnston SJ , Ridge SA , Cassidy J , et al.   Regulation of dihydropyrimidine dehydrogenase in colorectal cancer . Clin Cancer Res . 1999;5:2566–2570
  32. Salonga D , Danenberg KD , Johnson M , et al.   Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase . Clin Cancer Res . 2000;6:1322–1327
  33. Kornmann M , Link KH , Galuba I , et al.   Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer . J Gastrointest Surg . 2002;6:331–337
  34. Harris BE , Song R , Soong SJ , et al.   Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion . Cancer Res . 1990;50:197–201
  35. Levi FA , Zidani R , Vannetzel JM , et al.   Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases (A randomized multi-institutional trial) . J Natl Cancer Inst . 1994;86:1608–1617
  36. Levi F , Zidani R , Misset JL  International Organization for Cancer Chronotherapy . Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer . Lancet . 1997;350:681–686
  37. Schilsky RL , Hohneker J , Ratain MJ , et al.   Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer . J Clin Oncol . 1998;16:1450–1457
  38. Baker SD , Khor SP , Adjei AA , et al.   Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase . J Clin Oncol . 1996;14:3085–3096
  39. Saltz LB , Cox JV , Blanke C , et al.  Irinotecan Study Group   Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer . N Engl J Med . 2000;343:905–914
  40. Douillard JY , Cunningham D , Roth AD , et al.   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer (A multicentre randomised trial) . Lancet . 2000;355:1041–1047
  41. Cunningham D , Pyrhonen S , James RD , et al.   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer . Lancet . 1998;352:1413–1418
  42. Rougier P , Van Cutsem E , Bajetta E , et al.   Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer . Lancet . 1998;352:1407–1412
  43. Ma MK , McLeod HL . Lessons learned from the irinotecan metabolic pathway . Curr Med Chem . 2003;10:41–49
  44. Gupta E , Lestingi TM , Mick R , et al.   Metabolic fate of irinotecan in humans (Correlation of glucuronidation with diarrhea) . Cancer Res . 1994;54:3723–3725
  45. Iyer L , King CD , Whitington PF , et al.   Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes . J Clin Invest . 1998;101:847–854
  46. Iyer L , Hall D , Das S , et al.   Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism . Clin Pharmacol Ther . 1999;65:576–582
  47. Iyer L , Das S , Janisch L , et al.   UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity . Pharmacogenomics J . 2002;2:43–47
  48. Ando Y , Saka H , Ando M , et al.   Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity (A pharmacogenetic analysis) . Cancer Res . 2000;60:6921–6926
  49. Innocenti F , Undevia SD , Iyer L , et al.   Genetic varaints in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan . J Clin Oncol . 2004;22:1382–1388
  50. Rothenberg M , Oza A , Butrger B , et al.   Final results of a phase III trial of 5-FU/leucovorin versus oxa;iplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin . Proc Am Soc Clin Oncol . 2003;22:252a; (abstr 1011)
  51. de Gramont A , Figer A , Seymour M , et al.   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer . J Clin Oncol . 2000;18:2938–2947
  52. Giacchetti S , Perpoint B , Zidani R , et al.   Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer . J Clin Oncol . 2000;18:136–147
  53. Goldberg RM , Sargent DJ , Morton RF , et al.   A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer . J Clin Oncol . 2004;22:23–30
  54. Park DJ , Stoehlmacher J , Zhang W , et al.   A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer . Cancer Res . 2001;61:8654–8658
  55. Stoehlmacher J , Ghaderi V , Iobal S , et al.   A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer . Anticancer Res . 2001;21:3075–3079
  56. Zhang K , Mack P , Wong KP . Glutathione-related mechanisms in cellular resistance to anticancer drugs . Int J Oncol . 1998;12:871–882
  57. Stoehlmacher J , Park DJ , Zhang W , et al.   Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer . J Natl Cancer Inst . 2002;94:936–942
  58. McLeod H , Sargent D , Marsh S , et al.   Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil/CPT-11, 5FU/oxaliplatin, or CPT-11/oxal therapy for advanced colorectal cancer (Results from an intergroup study) . Proc Am Soc Clin Oncol . 2003;22:253a; (abstr 1013)
  59. Tournigand C , Andre T , Achille E , et al.   FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer (A randomized GERCOR study) . J Clin Oncol . 2003;22:229–237
  60. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  61. Cunningham D , Humblet Y , Siena S , et al.   Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) . Proc Am Soc Clin Oncol . 2003;22:252a; (abstr 1012)
  62. Lenz HJ . Pharmacogenomics in colorectal cancer . Semin Oncol . 2003;30:47–53

PII: S0093-7754(04)00458-0

doi: 10.1053/j.seminoncol.2004.09.029

Seminars in Oncology
Volume 32, Issue 1 , Pages 113-119 , February 2005

Article Tools

* Image Usage & Resolution